A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam BID for 2 Weeks, Followed by QD for 4 Weeks, in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 100
- 主要终点
- Proportion of participants with clinical remission
研究概览
简要总结
The primary objective of this study is to evaluate the efficacy (as measured by induction of remission) of two dose levels (low and high) per age group (5 to <12 and 12 to ≤17 years) of budesonide rectal foam as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in pediatric subjects with active, mild to moderate distal ulcerative colitis (UC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 5 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and Female (non-pregnant and non-lactating) 5 to ≤17 years of age at Screening.
- •Established diagnosis of UC, based on clinical history, characteristic endoscopic findings, and histopathology results from biopsies.
- •Disease limited to the distal colon and rectum, (disease involving only the first 15 centimeters or less proximal to the anal verge).
- •Active, distal UC of mild or moderate severity, defined as a Modified Mayo Clinic Score (mMCS) between 4 and 8, inclusive, that includes an endoscopy subscore ≥ 2 and a rectal bleeding subscore ≥
- •If on a background oral 5-ASA, the dose and formulation have remained unchanged for at least 6 weeks prior to Visit 2 (Run-In) and the subject is willing to remain on the same dosage form and regimen for the duration of the study.
排除标准
- •Current or prior diagnosis of Crohn's disease or indeterminate colitis.
- •Ulcerative colitis involving the proximal colon - i.e, the sigmoid, left, transverse, and/or ascending colon and cecum;
- •Severe UC, defined as an mMCS >
- •Infectious colitis (based on positive microbiologic tests at Screening) or any recent history of infectious colitis (within 30 days of Screening).
- •Prior gastrointestinal surgery, except appendectomy or hernia (e.g., inguinal, umbilical).
- •NOTE: Prior cholecystectomy is not exclusionary if more than 1 year prior to Screening.
- •Evidence or history of toxic megacolon or bowel resection.
- •Active proctologic pathology such as hemorrhoids, fistulas and fissures or other historical anatomic problems which would impair rectal administration (e.g., cloaca, imperforate anus history)
研究组 & 干预措施
High dose budesonide rectal foam
干预措施: High dose budesonide rectal foam (Drug)
Low dose budesonide rectal foam
干预措施: Low dose budesonide rectal foam (Drug)
Matching placebo rectal foam
干预措施: Matching placebo rectal foam (Drug)
结局指标
主要结局
Proportion of participants with clinical remission
时间窗: Day 42
Clinical remission based on the modified Mayo Clinic Score, defined as an endoscopy score ≤ 1 (excluding friability), a rectal bleeding subscore of 0, and at least a 1-point decrease in stool frequency subscore from Baseline to achieve a stool frequency subscore ≤ 1. Each component is scored from 0 to 3, with total scores ranging from 0 to 9, with higher scores indicating more severe disease.
次要结局
- Proportion of participants who achieve a stool frequency subscale score of 0 at the end of six weeks of treatment.(Day 42)
- Proportion of participants who achieve a rectal bleeding subscale score of 0 at the end of six weeks of treatment(Day 42)
- Proportion of subjects who achieve an endoscopy subscale score of 0 or 1 at the end of six weeks of treatment.(Day 42)